Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a ...

Hikma Pharmaceuticals said on Thursday that it has entered into a preliminary $50m class settlement agreement that resolves ...

Hikma Pharmaceuticals Plc reached a $50 million deal to settle claims it colluded with other drugmakers to delay the generic version of brand-name narcolepsy drug Xyrem.

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday announced it has reached a settlement deal for up to USD50 million in cash for litigation brought against the firm in relation to its narcolepsy ...

Jazz Pharmaceuticals PLC (JAZZ) reports robust Q1 2025 performance with significant revenue growth in neuroscience, despite a ...

Jazz Pharmaceuticals ( NASDAQ: JAZZ) shares fell after the market on Tuesday as the company lowered its full year bottom-line expectation, to reflect the impact of the Chimerix deal and certain Xyrem ...

Xyrem (sodium oxybate) is a brand-name oral solution that’s prescribed for certain narcolepsy symptoms. Xyrem has interactions with alcohol, some other drugs, and certain supplements.

As with other drugs, Xyrem (sodium oxybate) can cause side effects, such as nausea, vomiting, and dizziness. If side effects of Xyrem become difficult to tolerate, talk with your doctor or pharmacist.

It posted quarterly Xyrem net product sales down 42% to $37.2M, while Xywav net product sales rose 9% to $344.8M. The stock is down 5.6% in post market trading.

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. Early this week ...